Ver registro no DEDALUS
Exportar registro bibliográfico

Metrics


Metrics:

Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting (2009)

  • Authors:
  • USP affiliated authors: CARAMELLI, BRUNO - FM
  • USP Schools: FM
  • DOI: 10.1007/s00392-008-0722-1
  • Subjects: CONTENEDORES; INFARTO DO MIOCÁRDIO; CORONARIOPATIA; ANTIBIÓTICOS
  • Language: Inglês
  • Imprenta:
  • Source:
  • Acesso online ao documento

    Online accessDOI or search this record in
    Informações sobre o DOI: 10.1007/s00392-008-0722-1 (Fonte: oaDOI API)
    • Este periódico é de assinatura
    • Este artigo NÃO é de acesso aberto
    • Cor do Acesso Aberto: closed
    Informações sobre o Citescore
  • Título: Journal of Neurology

    ISSN: 0340-5354

    Citescore - 2017: 3

    SJR - 2017: 1.626

    SNIP - 2017: 1.314


  • Exemplares físicos disponíveis nas Bibliotecas da USP
    BibliotecaCód. de barrasNúm. de chamada
    FM10700092446-SFM BCSEP 068 2008
    How to cite
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

    • ABNT

      IKEOKA, Dimas T.; VIEIRA, Carolina Z.; LEMOS, Pedro A.; et al. Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting. Clinical research in cardiology, Darmstadt, v. 98, p. 44-51, 2009. Disponível em: < http://www.springerlink.com/content/b271m5gm74669094/fulltext.pdf > DOI: 10.1007/s00392-008-0722-1.
    • APA

      Ikeoka, D. T., Vieira, C. Z., Lemos, P. A., Strabelli, T. V., Silva, E. E. R., Perin, M. A., et al. (2009). Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting. Clinical research in cardiology, 98, 44-51. doi:10.1007/s00392-008-0722-1
    • NLM

      Ikeoka DT, Vieira CZ, Lemos PA, Strabelli TV, Silva EER, Perin MA, Groselj-Strele A, Tiran B, Tiran A, Caramelli B. Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting [Internet]. Clinical research in cardiology. 2009 ; 98 44-51.Available from: http://www.springerlink.com/content/b271m5gm74669094/fulltext.pdf
    • Vancouver

      Ikeoka DT, Vieira CZ, Lemos PA, Strabelli TV, Silva EER, Perin MA, Groselj-Strele A, Tiran B, Tiran A, Caramelli B. Azithromycin does not prevent six-month myointimal proliferation but attenuates the transient systemic inflammation occurring after coronary stenting [Internet]. Clinical research in cardiology. 2009 ; 98 44-51.Available from: http://www.springerlink.com/content/b271m5gm74669094/fulltext.pdf

    Referências citadas na obra
    Azar RR, McKay RG, Kiernan FJ, Seecharran B, Feng YJ, Fram DB, Wu AH, Waters DD (1997) Coronary angioplasty induces a systemic inflammatory response. Am J Cardiol 80:1476–1478
    Berk BC (2001) Vascular smooth muscle growth: autocrine growth mechanisms. Physiol Rev 81:999–1030
    Blasi F, Boman J, Esposito G, Melissano G, Chiesa R, Cosentini R, Tarsia P, Tshomba Y, Betti M, Alessi M et al (1999) Chlamydia pneumoniae DNA detection in peripheral blood mononuclear cells is predictive of vascular infection. J Infect Dis 180:2074–2076
    Boman J, Gaydos CA (2000) Polymerase chain reaction detection of chlamydia pneumoniae in circulating white blood cells. J Infect Dis 181(Suppl 3):S452–S454
    Cook S, Walker A, Hugli O, Togni M, Meier B (2007) Percutaneous coronary interventions in Europe: prevalence, numerical estimates, and projections based on data up to 2004. Clin Res Cardiol 96:375–382
    Dusek J, St’asek J, Tichy M, Bis J, Gregor J, Vojacek J, Masin V, Polansky P, Brtko M, Cernohorsky D (2006) Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin Chim Acta 367:77–80
    Gomes WJ, Buffolo E (2006) Coronary stenting and inflammation: implications for further surgical and medical treatment. Ann Thorac Surg 81:1918–1925
    Herdeg C, Gohring-Frischholz K, Helber U, Geisler T, May A, Haase KK, Gawaz M (2008) Successful local antiproliferative paclitaxel delivery in a repeatedly restenosed lesion of the right coronary artery after drug eluting-stent implantation. Clin Res Cardiol 97:49–52
    Higuchi ML, Sambiase N, Palomino S, Gutierrez P, Demarchi LM, Aiello VD, Ramires JA (2000) Detection of mycoplasma pneumoniae and chlamydia pneumoniae in ruptured atherosclerotic plaques. Braz J Med Biol Res 33:1023–1026
    Hojo Y, Ikeda U, Katsuki T, Mizuno O, Fukazawa H, Kurosaki K, Fujikawa H, Shimada K (2000) Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosis. Heart 84:83–87
    Kuo C, Campbell LA (2000) Detection of chlamydia pneumoniae in arterial tissues. J Infect Dis 181(Suppl 3):S432–S436
    Latsios G, Saetta A, Michalopoulos NV, Agapitos E, Patsouris E (2004) Detection of cytomegalovirus, helicobacter pylori and chlamydia pneumoniae DNA in carotid atherosclerotic plaques by the polymerase chain reaction. Acta Cardiol 59:652–657
    Lemos PA, Mercado N, van Domburg RT, Kuntz RE, O’Neill WW, Serruys PW (2004) Comparison of late luminal loss response pattern after sirolimus-eluting stent implantation or conventional stenting. Circulation 110:3199–3205
    McBride W, Lange RA, Hillis LD (1988) Restenosis after successful coronary angioplasty: pathophysiology and prevention. N Engl J Med 318:1734–1737
    Mollmann H, Elsasser A, Nef H, Schneider S, Nienaber CA, Richardt G, Weber M, Kelm M, Levenson B, Bonzel T et al (2008) Treatment of in-stent restenosis with sirolimus-eluting-stents: results from the prospective German Cypher stent registry. Clin Res Cardiol 97(7):432–440
    Morrow DA, Cannon CP, Jesse RL, Newby LK, Ravkilde J, Storrow AB, Wu AH, Christenson RH (2007) National academy of clinical biochemistry laboratory medicine practice guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation 115:e356–e375
    Neumann F, Kastrati A, Miethke T, Pogatsa-Murray G, Mehilli J, Valina C, Jogethaei N, da Costa CP, Wagner H, Schomig A (2001) Treatment of chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial. Lancet 357:2085–2089
    Ong, AT, van Domburg RT, Aoki J, Sonnenschein K, Lemos PA, Serruys PW (2006) Sirolimus-eluting stents remain superior to bare-metal stents at two years: medium-term results from the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. J Am Coll Cardiol 47:1356–1360
    Radke PW, Jain D, Conrad A, Thomsen C, Remmel M, Kurowski V, Schunkert H, Hartmann F (2008) Evaluation of the dedicated Frontiertrade mark coronary bifurcation stent: a matched pair analysis with drug-eluting and bare metal stents. Clin Res Cardiol 97:260–265
    Reiber JH, Serruys PW, Kooijman CJ, Wijns W, Slager CJ, Gerbrands JJ, Schuurbiers JC, den Boer A, Hugenholtz PG (1985) Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. Circulation 71:280–288
    Scheller B, Kuhler M, Cremers B, Mahnkopf D, Bohm M, Boxberger M (2008) Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. Clin Res Cardiol 97:118–123
    Schwartz RS, Murphy JG, Edwards WD, Camrud AR, Vliestra RE, Holmes DR (1990) Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 82:2190–2200
    Serruys PW, van Hout B, Bonnier H, Legrand V, Garcia E, Macaya C, Sousa E, van der Giessen W, Colombo A, Seabra-Gomes R et al (1998) Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet 352:673–681
    Smith SC, Jr, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, Fuster V, Gotto A, Grundy SM, Miller NH et al (2001) AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 38:1581–1583
    Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J et al (2004) One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 109:1942–1947
    Tiran A, Tio RA, Ossewaarde JM, Tiran B, den Heijer P, The TH, Wilders-Truschnig MM (1999) Coronary angioplasty induces rise in chlamydia pneumoniae-specific antibodies. J Clin Microbiol 37:1013–1017
    Tiran A, Tiesenhausen K, Karpf E, Orfila J, Koch G, Gruber HJ, Tsybrovskyy O, Tiran B (2004) Association of antibodies to chlamydial lipopolysaccharide with the endovascular presence of Chlamydophila pneumoniae in carotid artery disease. Atherosclerosis 173:47–54
    Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM (2001) Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 37:839–846
    Yetkin G, Yetkin E, Aksoy Y, Gurbuz OA, Mert A (2004) Changes in antibody titers against chlamydia pneumoniae after coronary angioplasty. Int J Cardiol 95:293–297